Description

ARACHITOL _ 6L (VIT D3) INJ

Indications

ARACHITOL _ 6L (VIT D3) INJ is primarily indicated for the treatment and prevention of vitamin D deficiency and insufficiency. It is particularly beneficial in conditions associated with malabsorption, such as celiac disease or chronic pancreatitis. Additionally, this injectable formulation is used in patients with osteoporosis, rickets, and osteomalacia, where adequate vitamin D levels are crucial for calcium absorption and bone health. It may also be indicated for patients undergoing long-term corticosteroid therapy, which can impair vitamin D metabolism.

Mechanism of Action

Vitamin D3, or cholecalciferol, is a fat-soluble vitamin that plays a vital role in calcium and phosphate metabolism. Upon administration, ARACHITOL _ 6L is converted in the liver to 25-hydroxyvitamin D (calcidiol) and subsequently in the kidneys to its active form, 1,25-dihydroxyvitamin D (calcitriol). This active form enhances intestinal absorption of calcium and phosphate, promotes bone mineralization, and regulates parathyroid hormone levels. By increasing serum calcium levels, vitamin D3 aids in maintaining bone density and overall skeletal health.

Pharmacological Properties

ARACHITOL _ 6L contains a high concentration of vitamin D3, which is essential for various physiological functions. The pharmacokinetics of vitamin D3 involves absorption through the gastrointestinal tract, followed by hepatic and renal metabolism. The half-life of vitamin D3 is approximately 15 days, allowing for sustained effects on calcium and phosphate homeostasis. The injectable form provides a rapid increase in serum vitamin D levels, making it particularly useful in patients who are unable to absorb oral supplements effectively.

Contraindications

ARACHITOL _ 6L (VIT D3) INJ is contraindicated in patients with known hypersensitivity to vitamin D or any of its components. It should not be used in individuals with hypercalcemia, hyperphosphatemia, or vitamin D toxicity. Patients with certain granulomatous diseases, such as sarcoidosis or tuberculosis, should also avoid this medication, as they may have increased sensitivity to vitamin D and may develop hypercalcemia.

Side Effects

While ARACHITOL _ 6L is generally well-tolerated, some patients may experience side effects. Common side effects include nausea, vomiting, and constipation. More serious adverse effects can occur, particularly with overdose, including hypercalcemia, which may manifest as confusion, weakness, and renal impairment. Patients should be monitored for signs of hypervitaminosis D, especially if they have underlying conditions that predispose them to elevated calcium levels.

Dosage and Administration

The dosage of ARACHITOL _ 6L (VIT D3) INJ varies based on the patient’s age, weight, and specific medical condition. For adults, the typical dose for vitamin D deficiency is 300,000 to 600,000 IU administered intramuscularly as a single injection or divided into multiple doses. For the treatment of osteoporosis, a healthcare provider may recommend a maintenance dose of 800 to 1000 IU daily. Pediatric dosing should be determined by a healthcare professional based on the child’s specific needs. It is essential to follow the healthcare provider’s instructions and not exceed the recommended dosage to avoid potential toxicity.

Interactions

ARACHITOL _ 6L may interact with various medications. The concurrent use of thiazide diuretics can increase the risk of hypercalcemia due to decreased renal excretion of calcium. Additionally, certain anticonvulsants, such as phenytoin and phenobarbital, may reduce the effectiveness of vitamin D by accelerating its metabolism. Patients taking corticosteroids may also require higher doses of vitamin D due to its effects on calcium absorption. It is crucial for patients to inform their healthcare provider of all medications they are taking to avoid potential interactions.

Precautions

Before initiating treatment with ARACHITOL _ 6L, it is essential to assess the patient’s vitamin D levels and overall health status. Regular monitoring of serum calcium and phosphate levels is recommended during therapy to prevent complications associated with hypercalcemia. Patients with renal impairment or a history of kidney stones should use this medication with caution. Pregnant and lactating women should consult their healthcare provider before using this product, as excessive vitamin D can have adverse effects on fetal and neonatal health. It is also advisable to maintain a balanced diet rich in calcium and phosphorus while on vitamin D therapy.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of vitamin D supplementation in improving bone health and preventing deficiency-related complications. A study published in the Journal of Bone and Mineral Research found that patients receiving vitamin D3 injections showed significant improvements in bone mineral density compared to those receiving placebo. Another study in the American Journal of Clinical Nutrition indicated that vitamin D supplementation reduced the incidence of falls and fractures in older adults. These findings underscore the importance of adequate vitamin D levels in maintaining skeletal health and preventing osteoporosis.

Conclusion

ARACHITOL _ 6L (VIT D3) INJ is a vital therapeutic option for managing vitamin D deficiency and its associated complications. With its effective mechanism of action and pharmacological properties, this injectable formulation provides rapid relief and is particularly beneficial for patients with malabsorption issues or those unable to take oral supplements. However, it is essential for patients to use this medication responsibly, under the guidance of a healthcare provider, to minimize the risk of side effects and interactions.